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MaThe term “inotrope” is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac
output with cardiogenic shock. Traditional inotropic agents exert their effect by modulating calcium signaling in the
myocardium. Their use is associated with poor long-term outcomes. Newer molecules in development intend to break
from calcium mediation and the associated detrimental long-term effects by targeting distinct mechanisms of action to
improve cardiac performance. Thus, “inotropy” does not sufﬁciently describe the range of potential novel pharmaceutical
products. To enhance communication around and evaluation of current, emerging, and potential therapies, this review
proposes a novel nuanced and holistic framework to categorize pharmacological agents that improve myocardial
performance based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations;
myotropes, which affect the molecular motor and scaffolding; and mitotropes, which inﬂuence energetics. Novel
chemical entities can easily be incorporated into this structure, distinguishing themselves based on their mechanisms
and clinical outcomes. (J Am Coll Cardiol 2019;73:2345–53) © 2019 The Authors. Published by Elsevier on behalf
of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).I notrope derives from Greek, meaning “sinew”and “tropic” meaning changing or affecting.The term inotropy has been broadly used for
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HIGHLIGHTS
 Traditional inotropic agents modulate
calcium signaling in the myocardium but
are associated with poor long-term
outcomes.
 Mechanistic nomenclature could improve
communication and recognize therapeu-
tic advances in myocardial functional
enhancement.
 Calcium-independent pharmaceuticals
may demonstrate better efﬁcacy and
ABBR EV I A T I ON S
AND ACRONYMS
ADP = adenosine diphosphate
ATP = adenosine triphosphate
Ca2þ = calcium ion
cAMP = cyclic adenosine
monophosphate
HFrEF = heart failure with
reduced ejection fraction
LVEF = left ventricular ejection
fraction
SR = sarcoplasmic reticulum
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2346burden from heart failure with reduced ejec-
tion fraction (HFrEF) (3). Because of this
vernacular, inotrope has become inter-
changeable with available pharmacological
agents that alter cardiac performance by
changing cardiac myocyte calcium ion (Ca2þ)
balance and ﬂux (4). The improvement in
contractility from these agents can be mani-
fested by increased left ventricular systolic
pressure generation per unit time (dP/dt)
and augmented hemodynamic performance,
including cardiac output and stroke volume.
This improvement can be visualized on imag-safety than available agents and should
continue to be developed.ing by an elevated left ventricular ejection fraction
(LVEF) or, in some cases, by subsequent reduction
of cardiac biomarkers, including natriuretic peptides.
Some of these agents may have additional secondary
effects, such as changes to vascular tone that may
contribute to their cardiac activities, although the
focus here is the load-independent effects of these
drugs. Unfortunately, the detrimental long-term ef-
fects of these agents on clinical outcomes for patients
with HFrEF are a direct consequence of their mecha-
nisms of action and have sullied the term inotrope
as a potential long-term therapeutic option.
With continued use, conventional inotropic agents—
including catecholamines, phosphodiesterase-3 in-
hibitors, sodium-potassium adenosine triphosphatase
(ATPase) inhibitors, and mixed-mechanism calcium
sensitizers and phosphodiesterase-3 inhibitors—
detrimentally alter myocardial energetics, decrease
the adenosine triphosphate (ATP)/adenosine diphos-
phate (ADP) ratio, and have been associated with
clinical outcomes that are at best neutral and at worst
deadly, including malignant arrhythmias (4). The
underlying Ca2þ-centric mechanism of these agents
may be the dual-edged sword that causes both
their inotropic and detrimental effects. In contrast,
well-established HFrEF medical therapies improve
myocardial contractility and mortality over time
without increasing cardiomyocyte Ca2þ ﬂuxes (5).
New pharmacological agents that alter myocardial
performance and contraction by novel means may be
able to further improve myocardial energetics and
clinical outcomes for patients with HFrEF. Direct
contractionpromoting agents may avoid adverse
clinical effects by targeting new mechanisms of action
separate from conventional Ca2þ-acting medications.
Inotropy as currently used is an overly broad and
ill-deﬁned concept to describe therapies that improve
the pumping function of the heart. We therefore
propose a novel, more nuanced and holistic frame-
work for drugs that directly improve myocardial
performance to facilitate improved clinical andscientiﬁc communication, augment pharmaceutical
development, and hopefully enhance clinical care.
The suggested schema categorizes these entities in a
manner that incorporates future therapeutic agents
with distinct mechanisms of action, hemodynamic
consequences, and potential clinical beneﬁts. The
3 broad conceptualized areas (Table 1) that can
mechanistically be targeted are intracellular Ca2þ, the
physical sarcomere, and myocardial energetics.
We propose cardiac calcitropes, myotropes, and
mitotropes to describe these categories, respectively.
INOTROPY, CONTRACTILITY,
AND CONTRACTION
Typical deﬁnitions of inotropy refer to the function of
the myocardial contractile apparatus that is load-
independent. Two attributes can increase the phys-
ical impulse produced, the forcetime product:
increased force or longer contraction time.
 Cardiac contractility is conventionally manifested
by accelerated myocardial ﬁber shortening that
increases the rise in ventricular dP/dt and leads to
an elevated peak tension. Contractility is load-
independent and deﬁned as the ability of the
myocardium to generate force per unit time.
 In contrast, contraction is the measure of short-
ening of the underlying myocardial structure, the
sarcomere. Although increased contraction can
occur because of augmented contractility,
contraction can also increase independently of
load or dP/dt by mechanisms that prolong the
duration of contraction.
Loading changes can also affect cardiac function;
for instance, vasodilation and decreased afterload can
increase contraction speed with stable contractility.
Many typical measurements of ventricular function,
TABLE 1 Currently Available and Developmental Direct Inotropic Agents
Pharmacological Agent Mechanism dP/dt Hemodynamic Effects Patient Outcomes
Cardiac calcitropes
Dobutamine Catecholamine: b-adrenergic receptor/ cAMP/ [ Ca2þ [ [ Cardiac output [ Mortality
Dopamine Catecholamine: b-adrenergic receptor/ cAMP/ [ Ca2þ [ [ Cardiac output [ Mortality
Epinephrine Catecholamine: b-adrenergic receptor/ cAMP/ [ Ca2þ [ [ Cardiac output [ Mortality
Milrinone Phosphodiesterase-3 inhibitor: cAMP/ [ Ca2þ [ [ Cardiac output [ Mortality
Levosimendan Phosphodiesterase-3 inhibitor (and calcium sensitizer):
Y Troponin and tropomyosin inhibition; cAMP/ [ Ca2þ
[ [ Cardiac output ?[ Mortality
Cardiac glycosides Naþ-Kþ ATPase inhibitor: YNCX Ca2þ extrusion/ [ Ca2þ [ 4 Cardiac output ?4Mortality
Y Hospitalizations
Istaroxime Naþ-Kþ ATPase Inhibitor & SERCA2a Activator:
YCa2þ extrusion/ [ Ca2þ, [ SERCA2a/ [ Ca2þ in SR
[ [ Cardiac output ?
Cardiac myotropes
Omecamtiv mecarbil Direct myosin activator
[ Myosin participation in systole
4 [ Cardiac output ?
Cardiac mitotropes
Perhexiline Carnitine palmitoyl transferase inhibitor:
Y Mitochondrial fatty acids/ [ Glucose metabolism
4 [ Cardiac output ?
Trimetazidine Thiolase I inhibitor: Y Fatty acid oxidation/ [ Glucose metabolism [ [ Cardiac Output ?
Elamipretide Cardiolipin stabilizer
[ Adenosine triphosphate synthesis
? ? ?
[ ¼ increase; Y ¼ decrease;4 ¼ no change; ? ¼ unknown or possible; ATPase ¼ adenosine triphosphatase; Ca2þ ¼ calcium ion; cAMP ¼ cyclic adenosine monophosphate;
K ¼ potassium; Na ¼ sodium; NCX ¼ sodium ion/calcium ion exchanger; SERCA2a ¼ sarcoplasmic/endoplasmic reticulum calcium ATPase; SR ¼ sarcoplasmic reticulum.
J A C C V O L . 7 3 , N O . 1 8 , 2 0 1 9 Psotka et al.
M A Y 1 4 , 2 0 1 9 : 2 3 4 5 – 5 3 Cardiac Calcitropes, Myotropes, and Mitotropes
2347such as measurement of LVEF by imaging or hemo-
dynamically measured cardiac output, are load-
dependent. Although these can be useful clinical
metrics, they are often conﬂated with contractility in
clinical settings, and they fail to assess the isolated
contractile status of the myocardium. Thus, although
pure vasodilators may improve LVEF or stroke vol-
ume, they cannot be considered inotropes.
MYOCARDIAL CONTRACTILE APPARATUS
AND ENERGETICS
Available inotropic agents and those currently in
development alter ventricular systolic performance
by affecting the myocardial machinery. The 3 broad
components of this machinery are: 1) the contractile
elements that consist of the myosin motor, actin
ﬁlaments, and the regulatory proteins, including the
troponintropomyosin complex that impede actin
and myosin interactions; 2) the Ca2þ cycling elements
responsible for the storage and ﬂux of myocardial
Ca2þ; and 3) the energetic elements that include ATP
produced by the mitochondria required for myosin
activity (Central Illustration).
Myosin is the critical molecular motor that con-
verts energy stored as ATP into contractile force. It is
the active enzyme of the myocardial forceproducing
structure, the sarcomere. Sarcomeric myosin exists as
thick ﬁlaments interdigitated between the thin ﬁla-
ments of actin on which it pulls to mediatecontraction (6,7). Actin-associated troponin and
tropomyosin enable the intracellular Ca2þ status
and other factors to regulate the myosinactin
interaction. At basal intracellular Ca2þ levels before
contraction, tropomyosin complexed with troponins
blocks actinmyosin crossbridge formation. When
stimulatory electrical action potentials activate car-
diac myocytes, Ca2þ enters the cell by sarcolemmal
L-type Ca2þ channels and triggers secondary larger
Ca2þ release from the sarcoplasmic reticulum (SR)
through ryanodine receptors (8). The elevated Ca2þ
binds to troponin C and induces a positional change
in tropomyosin that disinhibits actinmyosin cross
bridging.
Once actin is available for binding in response to
increased cytosolic Ca2þ and troponin and/or tropo-
myosin movement, the myosin mechanochemical
cycle can proceed (7). Myosin in the primed state,
which is associated with a lone phosphate moiety
following hydrolysis of ATP to ADP, weakly interacts
with the actin ﬁlaments. Myosin only enters the
contractile cycle from this primed state, because
release of the phosphate transitions the myosin to a
strong interaction with actin. The power stroke that
occurs, the mechanical transduction of the myosin
lever arm, generates force and moves the actin
myoﬁlament approximately 10 nm (9). Following
the power stroke, ATP rapidly binds to myosin and
dissociates it from the actin myoﬁlament to reset
the lever arm for another power stroke.
CENTRAL ILLUSTRATION The Myocardial Contractile Apparatus and Classes of Therapeutic Agents
Psotka, M.A. et al. J Am Coll Cardiol. 2019;73(18):2345–53.
The 3 broad components of the myocardial machinery are the contractile elements and regulatory proteins in the sarcomere, the calcium ion (Ca2þ) cycling elements in
the cell and sarcoplasmic reticulum membranes, and the energetic elements, including adenosine triphosphate (ATP) produced by the mitochondria. Pharmacological
agents that improve myocardial performance can be described by this framework: calcitropes alter intracellular calcium concentrations; myotropes affect the molecular
motor and scaffolding; and mitotropes inﬂuence energetics. ADP ¼ adenosine diphosphate; cAMP ¼ cyclic adenosine monophosphate; CoA ¼ coenzyme A;
K ¼ potassium; Na ¼ sodium; Pi ¼ inorganic phosphate; SERCA ¼ sarcoplasmic/endoplasmic reticulum calcium ATPase; TCA ¼ tricarboxylic acid cycle.
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2349Concomitantly, following cell depolarization, Ca2þ is
returned to the SR by the sarcoplasmic/endoplasmic
reticulum calcium ATPase 2a (SERCA2a) and passed
into the extracellular space by the sodiumcalcium
exchanger and a calcium ATPase. The power stroke
occurs during cardiac systole following the electro-
cardiographic QRS as the correlate of the Ca2þ inﬂux.
The resetting of the molecular motor takes place
during diastole, and the Ca2þ efﬂux is visualized as
the electrocardiographic T-wave.
Myocardial excitationcontraction coupling, as
described previously, and the resulting ventricular
systole requires substantial ATP; without regenera-
tion, the process would use all intracellular ATP
within 1 min (10). The intramyocardial power source
responsible for providing energy to the myocardial
contraction apparatus is the mitochondrion (11). The
intracellular processing of fatty acids and glucose
produces carrier molecules that deliver electrons to
the mitochondrial electron transport chain, estab-
lishing a proton gradient and driving mitochondrial
ATP synthase to produce ATP. In normally func-
tioning myocardium, fatty acids are the primary en-
ergy source. Elevated intracellular and mitochondrial
Ca2þ participates in regulation of energy production
by activating enzymes for fatty acid processing
and thus increasing delivery of electrons required for
ATP production (12). However, additional stimuli
such as elevated intracellular ADP also accelerate the
production of ATP to maintain sufﬁcient energetic
reserve.
TRADITIONAL INOTROPES:
CARDIAC CALCITROPES
Inotropy produced by conventional agents, including
catecholamines, phosphodiesterase-3 inhibitors, and
cardiac glycosides (e.g., digitalis), all increase
myocardial force production by altering the concen-
tration of intracellular Ca2þ. The augmented Ca2þ by
these agents offsets the observed decrement of Ca2þ
in the SR of patients with HFrEF caused by ryanodine
receptor leak (8). Because the effects are all mediated
by altered Ca2þ, these agents are proposed to be
called cardiac calcitropes. The calcitropes are deﬁned
by their direct myocardial action rather than
their secondary effects on vascular tone and chrono-
tropy, both of which may also alter cardiac
performance.
Catecholamines such as dobutamine, dopamine,
epinephrine, and norepinephrine activate membrane-
bound, G-protein coupled adrenergic receptors that
stimulate adenylyl cyclase to transform ATP into cy-
clic adenosine monophosphate (cAMP) (4,13). Proteinkinase A activated by cAMP phosphorylates multiple
downstream targets, including phospholamban
(which increases SR Ca2þ uptake by SERCA2a), the
ryanodine receptors (which then release more Ca2þ
during depolarization), and troponin C (which
facilitates actin exposure for myosin). These Ca2þ-
mediated effects increase cardiac contractility.
The phosphodiesterase-3 inhibitors (e.g., milri-
none) also exert their effects through cAMP, by
blocking its degradation and stimulating protein
kinase A to activate the same downstream Ca2þ
cascade as catecholamines (4). Levosimendan is a
phosphodiesterase inhibitor, although it also sensi-
tizes the troponin and tropomyosin complex to
facilitate unmasking of the myosin-binding site on
actin, and has distinct vasodilatory effects mediated
by potassium channel activation (14–16). The cardiac
glycosides are sodiumpotassium ATPase inhibitors
that impede establishment of the sodium gradient
used by the sodiumcalcium exchanger to extrude
Ca2þ. This shift increases intracellular Ca2þ to facili-
tate contraction. Although cardiac glycosides do
increase dP/dt, they do not markedly change cardiac
output in clinical studies, perhaps due to concomitant
vasoconstriction and slowing of the heart rate (17–19).
Istaroxime is a nonglycoside sodiumpotassium
ATPase inhibitor that may also improve SERCA2a
activity. Although it elevated cardiac output in a
phase 2 randomized controlled trial, its development
program was halted by the manufacturer (20).
Although these cardiac calcitropes can improve
symptoms and may have a role in acute shock,
bridging to transplantation, and for palliation,
observational cohorts and randomized clinical trials
have shown that long-term use of catecholamines
and phosphodiesterase-3 inhibitors is associated with
increased mortality in patients with HFrEF (21–27).
Levosimendan has been associated with similar
mortality as the catecholamines (28–30). In 1 large-
scale trial, the cardiac glycosides decreased heart
failure hospitalizations, but did not improve mortal-
ity in HFrEF patients and were associated with
harm in some modern observational cohorts (31).
The unifying mechanism by which each of these
agents enhance cardiac contractility is increased
intracellular Ca2þ, and this mechanism may be
why they have been unable to improve long-term
survival of patients with HFrEF.
CARDIAC MYOTROPES
Because myosin is the central actor of the
sarcomere, therapeutics that target the myosin, actin,
the associated regulatory proteins, or other structural
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2350elements of the sarcomere through calcium-
independent mechanisms are proposed to be called
cardiac myotropes. Calcium sensitizers acting on
regulatory troponin and tropomyosin independently
of Ca2þ ﬂuxes would be considered cardiac myo-
tropes, and the calcitrope levosimendan also has this
myotropic activity. Myosin is an attractive therapeu-
tic target because it performs the work of myocardial
contraction and may participate in wasteful actin-
independent ATP hydrolysis outside of the myosin
mechanochemical cycle. The myotrope currently
under study, omecamtiv mecarbil, directly activates
cardiac myosin in a calcium-independent manner by
allosterically modulating its activity (32). By binding
to myosin and stabilizing the pre-powerstroke ener-
getic state, omecamtiv mecarbil increases the number
of myosin heads that enter the force-producing
state that are able to pull on actin ﬁlaments during
depolarization; it also appears to decrease inefﬁcient
actin-independent noncontractile energy usage.
Omecamtiv mecarbil does not alter Ca2þ-dependent
second messenger signaling to alter contractile func-
tion (32).
Direct myosin activation by omecamtiv mecarbil
raises the total amount of time spent in contraction
and systole without increasing the rate of force gen-
eration (dP/dt). Conceptually, cardiac myotropes and
cardiac calcitropes both increase the forcetime
product, but although calcitropes increase the force
generated per unit time, known myotropes increase
the time spent expending a given force. At stable
loading conditions, elevated cardiac myotropy aug-
ments the duration of ventricular systole, the systolic
ejection time, and thus, aortic blood ﬂow for each
contraction. Myotropes also appear to be energeti-
cally distinct from calcitropes. Although calcitropes
require increased oxygen use to augment the dP/dt,
myotropes appear to increase contraction without
greater oxygen consumption; thus, they improve
the overall efﬁciency of the mechanochemical system
(9,32).
The clinical usefulness of the myotrope omecamtiv
mecarbil is currently being evaluated in a phase
3 randomized controlled multicenter clinical trial
(GALACTIC-HF [Registrational Study With Ome-
camtiv Mecarbil/AMG 423 to Treat Chronic Heart
Failure With Reduced Ejection Fraction]; NCT02929329).
Data from earlier investigations suggest that its
alternative mechanism of action may improve clinical
outcomes compared with the cardiac calcitropes
(33,34). Long-term oral dosing of the compound to
patients with stable HFrEF decreases natriuretic
peptide biomarkers and improves ventricular di-
mensions (5,35). This agent is the ﬁrst in the classof pure cardiac myotropes. Nevertheless, even if
omecamtiv mecarbil was unable to improve or even
impair clinical outcomes for patients with HFrEF,
the premise of increasing myocardial contractile
performance by targeting the myosin motor or other
sarcomeric elements would remain an intuitive
therapeutic target that justiﬁes appropriately
descriptive terminology.
CARDIAC MITOTROPES
Myocardial energetics are centered around mito-
chondrial energy production, and drugs acting at the
mitochondria are therefore proposed to be called
mitotropes. Myocardial energetics are an attractive
target because of the energy dependence of myocar-
dial contraction and the metabolic derangements
present in the myocardium of patients with HFrEF.
The primary oxidation substrates transition from
fatty acids to glucose, and there is a reduction in
myocardial ATP (36,37).
Multiple chemical entities that affect the mito-
chondrion or alter myocardial metabolism are in
various stages of pre-clinical and clinical develop-
ment and clinical use. Perhexiline inhibits the protein
that translocates fatty acids into the mitochondria
under the premise that the shift to the more efﬁcient
ATP production through glucose is beneﬁcial (38).
Changes in myocardial contractile activity have been
variable in small clinical studies with perhexiline,
although it does appear to improve myocardial ener-
getics in patients with HFrEF (38,39). Alternatively,
trimetazidine blocks the mitochondrial oxidation of
fatty acids by the enzyme thiolase and similarly shifts
metabolism towards glucose (40). Small cohorts and
open-label randomized studies suggest trimetazidine
improves myocardial performance and contractility
as measured by increased LVEF, tissue Doppler ve-
locities, and cardiac output, and that it clinically
beneﬁts patients with HFrEF (41–44). However, these
results have not been reproduced in more appropri-
ately sized randomized controlled trials. Coenzyme
Q10 is a component of the mitochondrial electron
transport chain that appeared to decrease cardiovas-
cular and all-cause mortality in a small HFrEF trial
with a low event rate (45). No adequately sized trial
has conﬁrmed these results. Elamipretide stabilizes
the essential phospholipid cardiolipin within the
ATP-producing inner mitochondrial membrane,
which is believed to enhance ATP synthesis. Elami-
pretide seemed to increase left ventricular function,
as manifested by elevated LVEF and cardiac output
in dogs with HFrEF, although it was also associated
with vasodilatory effects and upregulation of
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ranging study in patients with HFrEF demonstrated
acute reductions in left ventricular volumes with
the highest dose of elamipretide; however, LVEF
and global longitudinal strain were unchanged (48).
CLASSIFICATION OF CURRENT HEART
FAILURE MEDICAL THERAPY
Current guideline-directed neurohormonal antago-
nists for HFrEF improve myocardial activity over
time through load-dependent and load-independent
actions, including by ventricular remodeling (5,49).
The inotropic subclassiﬁcations introduced previ-
ously can enhance mechanistic evaluation of these
neurohormonal agents. Focusing on these concepts
suggests that speciﬁc combinations of calcitropic,
myotropic, and mitotropic activities may be more
likely to provide survival and myocardial performance
beneﬁts similar to neurohormonal antagonism.
For instance, beta-adrenergic receptor antagonists
directly decrease contractility in the ﬁrst few months
of therapy by blocking cAMP formation and the Ca2þ
cascade, although LVEF improves in that time due to
remodeling and loading changes (50). Beta-adrenergic
antagonists can therefore be classiﬁed as direct nega-
tive calcitropes. Myocardial contractility rebounds
between 3 to 6 months, with continued treatment
associated with improvements in myocardial energy
efﬁciency, which suggests that beta-adrenergic
receptor antagonists also act as indirect positive
mitotropes (50,51).
Antagonists of the renin-aldosterone-angiotensin
system can also be characterized by these concepts.
Mineralocorticoid receptor antagonists appear to
reduce Ca2þ ﬂuxes and function as negative calci-
tropes (52). These agents may improve contractility
by increasing myosin ATPase activity in addition to
their effects on loading and remodeling, and thus
they may also be positive myotropes (5,53).
Angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers inhibit the increase in
Ca2þ-mediated myocyte contractility induced by
angiotensin 2 (54,55). Although it remains unclear
whether this suppression is due to antagonism of
angiotensin 2augmented Ca2þ ﬂuxes (calcitropy) or
increased Ca2þ sensitivity (myotropy), it is possible
that each major class of HFrEF therapeutics directly
antagonizes calcitropy. This activity of angiotensin-
converting enzyme inhibitors and angiotensin
receptor blockers is in addition to blocking the
ﬁbrotic, hypertrophic, ventricular loading, and
apoptotic effects of angiotensin 2 (56). Because
established therapeutics for HFrEF commonlyfunction as negative calcitropes, albeit with
concomitant beneﬁcial changes on ventricular
loading, remodeling, and noncalcitropic myocardial
performance enhancement, it may be that avoidance
of calcitropic activity should be sought in developing
new HFrEF therapeutics.
CONCLUSIONS AND FUTURE DIRECTIONS
The goal of optimizing cardiac function, the load-
independent contractile activity of the myocardium,
is a valuable target for novel therapeutics to treat
HFrEF. It remains unclear whether pharmaceuticals
that use mechanisms other than Ca2þ to directly boost
myocardial contractile action will demonstrate better
efﬁcacy and safety than currently available agents. To
improve communication around current agents, to
revise the clinical concept of improved myocardial
performance, and to permit and to encourage accu-
rate evaluation of potential new therapies that
enhance myocardial contractility and contraction, we
have proposed a framework based on mechanisms of
action. These mechanisms include 3 basic myocardial
processes: Ca2þ-based regulation; the molecular mo-
tor and sarcomeric scaffolding; and energetics.
Agents that primarily alter Ca2þ intracellular con-
centrations should be called cardiac calcitropes, those
that directly affect myosin or other components of
the sarcomere should be called cardiac myotropes,
and those that alter myocardial energetics should be
called cardiac mitotropes. Novel chemical entities can
easily be incorporated into this structure, dis-
tinguishing themselves based on their mechanisms of
action and effects on clinical outcomes. The reviewed
data suggest that therapeutic pathways that avoid
or perhaps antagonize calcitropy may be more
likely to improve long-term myocardial function
and clinical outcomes, and should be targeted for
development. This classiﬁcation will enhance
communication during drug discovery, facilitate
investigation into mechanisms of action and efﬁcacy,
and inform clinical discussions even if the agents
currently under evaluation fail to demonstrate
clinical beneﬁt.
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